• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-09-17

  The reference paper provides an integrated clinical pharmacology review of dabigatran etexilate as the first marketed oral direct thrombin inhibitor in the United States. Its central contribution is to connect prodrug activation, predictable pharmacokinetics, clinical efficacy, renal handling, bleeding risk, and therapeutic positioning across venous thromboembolism and nonvalvular atrial fibrillation.

• Capsaicin as a KDM1A/LSD1 Inhibitor

  2026-09-16

  The reference study identifies capsaicin, or (E)-Capsaicin, as a direct, reversible, FAD-competitive inhibitor of KDM1A/LSD1. Its biochemical activity was connected to reduced gastric cancer cell migration and invasion through epithelial–mesenchymal transition, providing a mechanistic link between a dietary natural product and histone methylation biology.

• Capsaicin: From TRPV1 to Epigenetic Translation

  2026-09-16

  Capsaicin is more than a sensory-neuron probe. Its established TRPV1 ion channel activation profile now sits alongside evidence for reversible KDM1A/LSD1 inhibition, creating a valuable but challenging translational model spanning pain signaling, inflammation signaling, and gastric cancer biology. This article outlines how to validate the dual mechanism, manage assay confounding, and design more informative workflows with (E)-Capsaicin.

• Hexamethonium Bromide for Autonomic Research

  2026-09-15

  Hexamethonium Bromide enables controlled interrogation of autonomic ganglionic transmission rather than relying on blood pressure changes alone. This practical guide connects fresh-solution handling, conscious telemetry, sex-aware hypertension models, and troubleshooting for more interpretable neuronal signaling experiments.

• 3D Organoid-Fibroblast Models of PDAC Chemoresistance

  2026-09-15

  Schuth et al. developed a patient-matched three-dimensional co-culture system that combines pancreatic ductal adenocarcinoma organoids with cancer-associated fibroblasts. The model showed that stromal fibroblasts increase organoid proliferation, reduce chemotherapy-induced cell death, and promote transcriptional programs associated with epithelial-to-mesenchymal transition, providing a more biologically complete framework for personalized drug-response studies.

• OPP: Reading Translation in Stressed B Cells

  2026-09-14

  O-propargyl-puromycin (OPP) offers a direct way to quantify nascent protein production when mitochondrial dysfunction reshapes B-cell behavior. This article connects OPP assay design with the Pcbp1-Fdxr mechanism while emphasizing controls, interpretation, and experimental limitations.

• Anti-ROR1 Antibody: Assay Design Beyond Pathways

  2026-09-14

  Anti-ROR1 Antibody (Zilovertamab) can strengthen ROR1 target-validation workflows when its role is separated from direct toxicology readouts. This article connects product-specific assay planning with mechanistic lessons from deoxynivalenol-induced liver injury while defining the evidence limits of that cross-domain application.

• 20-HETE–TRPV1 Signaling in Chronic Dermatitis

  2026-09-13

  The reference study identifies a peripheral mechanism by which chronic dermatitis converts normally painful capsaicin responses into itch: elevated 20-HETE activates TRPV1 on sensitized MrgprA3+ sensory neurons. Its combination of behavioral, genetic, electrophysiological, metabolomic, and pharmacological evidence links lipid metabolism to allokinesis and suggests that 20-HETE–TRPV1–MrgprA3 signaling is a tractable pathway for studying chronic itch.

• Magnetically Guided Biohybrid Microrobots for Tumors

  2026-09-12

  Gong et al. develop a deformable Euglena gracilis-based microrobot that combines magnetic guidance, autonomous tumor tropism, barrier penetration, and chlorophyll-dependent photodynamic functionality. The study provides a biohybrid strategy for navigating dense three-dimensional tumor models while retaining the adaptive motion of a living microorganism.

• Moxidectin Potentiates Polyenes in Oral Candidiasis

  2026-09-11

  A 2024 study found that moxidectin increases Candida albicans ergosterol biosynthesis, creating stronger synergy with amphotericin B and nystatin against planktonic growth, biofilms, and oral candidiasis in mice. Its genetic, transcriptomic, biochemical, and in vivo evidence supports ergosterol elevation as a counterintuitive strategy for potentiating polyene antifungal activity.

• Resiniferatoxin (RTX) Workflows for TRPV1 Research

  2026-09-11

  Resiniferatoxin (RTX) combines exceptional TRPV1 selectivity with durable sensory-neuron silencing, making it useful for calcium imaging, pain-model validation, and translational analgesia studies. This workflow-focused guide explains how to distinguish acute channel activation from lasting chemical inactivation and how to troubleshoot route, dose, and assay variability.

• HyperPFU™ High-Fidelity DNA Polymerase Guide

  2026-09-10

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates, especially when blunt-ended products are acceptable. It should not be selected for workflows that require 3′-A overhangs or sticky ends, and exact cycling conditions should be validated for each template.

• Ruthenium Red for Mechanotransduction Autophagy

  2026-09-10

  Ruthenium Red provides a water-soluble way to test whether Ca2+ flux contributes to compression-induced autophagy without treating calcium signaling as a single-channel phenomenon. This workflow combines calibrated mechanical loading, dose-aware calcium transport inhibition, imaging, immunoblotting, and practical controls for more defensible mechanotransduction studies.

• IPR-803: Urokinase Receptor Inhibitor

  2026-09-09

  IPR-803 is a small-molecule urokinase receptor inhibitor that blocks the uPAR–uPA protein–protein interaction. Biochemical, cellular, pharmacokinetic, and mouse-model data support its use as a research compound for tumor invasion, breast cancer metastasis, angiogenesis, and pancreatic tumor-stroma studies.

• Thioredoxin Control of CHK1 Inhibitor Sensitivity

  2026-09-09

  This Nature Communications study identifies thioredoxin 1 and redox control of ribonucleotide reductase as determinants of CHK1 inhibitor sensitivity in non-small cell lung cancer. Its findings support combining CHK1 inhibition with thioredoxin reductase blockade to disrupt deoxynucleotide production and replication-stress tolerance.

8080 records 1/539 page Next 12345 下5页 Last page